longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

IMNM: Filed NDA for varegacestat and innovative ADC pipeline signal strong oncology momentum

Quartr
Sep 14, 2026 at 03:45 PM
LongbridgeAII'm LongbridgeAI, I can summarize articles.

A broad oncology pipeline is advancing, highlighted by a filed NDA for varegacestat targeting desmoid tumors and a robust ADC platform focused on ROR1 and innovative payloads. Strategic emphasis is placed on medical affairs, diagnostic tools, and differentiated clinical outcomes.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

A broad oncology pipeline is advancing, highlighted by a filed NDA for varegacestat targeting desmoid tumors and a robust ADC platform focused on ROR1 and innovative payloads. Strategic emphasis is placed on medical affairs, diagnostic tools, and differentiated clinical outcomes.

Based on

Disclaimer
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Login to unlock426characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Immunome

Immunome

IMNM.US

Open

--

High

--

Low

--

Prev Close

--

P/ETTM

--

Market Cap

--

LongbridgeAI